Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Ironwood Pharma (IRWD) Stock Price & Analysis
217 Followers
IRWD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.53 - $15.70
Previous Close$8.12
Volume7.36M
Average Volume (3M)4.54M
Market Cap
$1.29B
Enterprise Value$1.91B
Total Cash (Recent Filing)$92.15M
Total Debt (Recent Filing)$715.54M
Price to Earnings (P/E)-1.2
Beta0.29
Next Earnings
May 09, 2024EPS Estimate
$0.2Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-6.51
Shares Outstanding156,528,648
10 Day Avg. Volume2,474,400
30 Day Avg. Volume4,538,622
Standard Deviation0.11
R-Squared0.08
Alpha-0.00732
Financial Highlights & Ratios
Price to Book (P/B)-3.63
Price to Sales (P/S)2.87
Price to Cash Flow (P/CF)8.90
P/FCF Ratio9.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.82
Enterprise Value/Gross Profit1.23
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$17.40Price Target Upside158.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ironwood Pharma News
PremiumPre-Earnings
Is IRWD a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyPositive results from the exploratory Phase 2 STARGAZE trial evaluating apraglutide show a favorable safety/tolerability profile and maintained lower GI tract responses.
Financial PerformanceWith LINZESS sales forecasted to reach $1.11 billion, Ironwood Pharmaceuticals is expected to generate significant revenue, alongside the potential accretive impact of apraglutide's launch.
Market PotentialMarket expansion opportunity is real, with potential to hit $1B in sales due to the differentiation of apraglutide with weekly dosing and a strong sales force.
Bears Say
Clinical Trial ResultsApraglutide's Phase 3 SBS trial missed on CIC ≥1 day off PS & enteral autonomy secondary endpoints.
Financial PerformancePrice erosion due to the removal of the Medicaid AMP cap poses a near-term headwind for Linzess revenue sales.
Market SentimentAfter rallying into the data, the stock experienced a significant sell-off.
---
Ownership Overview
24.53% Insiders
29.73% Mutual Funds
42.87% Other Institutional Investors
2.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $7.53 and its highest was $15.70 in the past 12 months.
What is Ironwood Pharma’s market cap?
Currently, no data Available
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is May 09, 2024 which is yesterday.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Feb 15, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.2 by -$0.21.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.29 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is $0.2.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 158,957,120 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.2. Following the earnings report the stock price went down -2.977%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Among the largest hedge funds holding Ironwood Pharma’s share is Driehaus Capital Management LLC. It holds Ironwood Pharma’s shares valued at 18M.
---
Ironwood Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.40 (158.16% Upside)
$17.40 (158.16% Upside)
Blogger Sentiment
Neutral
IRWD Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 20.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.74%
12-Months-Change
Fundamentals
Return on Equity
-654.88%
Trailing 12-Months
Asset Growth
-57.20%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q4 2024
0:00 / 0:00
---
IRWD Stock 12 Month Forecast
Average Price Target
$17.40
▲(158.16% Upside)
Technical Analysis
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+11.99%
reiterated a buy rating 10 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +11.99% per trade.
---